التفاصيل البيبلوغرافية
| العنوان: |
Twelve-Month Outcomes After Transplant of Hepatitis C-Infected Kidneys Into Uninfected Recipients: A Single-Group Trial. |
| المؤلفون: |
Reese, Peter P, Abt, Peter L, Blumberg, Emily A, Van Deerlin, Vivianna M, Bloom, Roy D, Potluri, Vishnu S, Levine, Matthew, Porrett, Paige, Sawinski, Deirdre, Nazarian, Susanna M, Naji, Ali, Hasz, Richard, Suplee, Lawrence, Trofe-Clark, Jennifer, Sicilia, Anna, McCauley, Maureen, Gentile, Caren, Smith, Jennifer, Niknam, Bijan A, Bleicher, Melissa |
| المصدر: |
Annals of Internal Medicine; 8/7/2018, Vol. 169 Issue 3, pN.PAG-N.PAG, 1p |
| مصطلحات موضوعية: |
KIDNEY transplantation, HEPATITIS C, KIDNEY exchange, GLOMERULAR filtration rate, ORGAN donors, PATIENTS, RESEARCH, COMBINATION drug therapy, VIRAL load, HETEROCYCLIC compounds, RESEARCH methodology, RNA, ANTIVIRAL agents, SURGICAL complications, HEPATITIS viruses, EVALUATION research, MEDICAL cooperation, TREATMENT effectiveness, IMIDAZOLES, COMPARATIVE studies, QUALITY of life, GENOTYPES, QUESTIONNAIRES, IMMUNOSUPPRESSIVE agents, LIVER failure, CREATININE, DISEASE complications |
| مستخلص: |
Background: Organs from hepatitis C virus (HCV)-infected deceased donors are often discarded. Preliminary data from 2 small trials, including THINKER-1 (Transplanting Hepatitis C kidneys Into Negative KidnEy Recipients), suggested that HCV-infected kidneys could be safely transplanted into HCV-negative patients. However, intermediate-term data on quality of life and renal function are needed to counsel patients about risk.Objective: To describe 12-month HCV treatment outcomes, estimated glomerular filtration rate (eGFR), and quality of life for the 10 kidney recipients in THINKER-1 and 6-month data on 10 additional recipients.Design: Open-label, nonrandomized trial. (ClinicalTrials.gov: NCT02743897).Setting: Single center.Participants: 20 HCV-negative transplant candidates.Intervention: Participants underwent transplant with kidneys infected with genotype 1 HCV and received elbasvir-grazoprevir on posttransplant day 3.Measurements: The primary outcome was HCV cure. Exploratory outcomes included 1) RAND-36 Physical Component Summary (PCS) and Mental Component Summary (MCS) quality-of-life scores at enrollment and after transplant, and 2) posttransplant renal function, which was compared in a 1:5 matched sample with recipients of HCV-negative kidneys.Results: The mean age of THINKER participants was 56.3 years (SD, 6.7), 70% were male, and 40% were black. All 20 participants achieved HCV cure. Hepatic and renal complications were transient or were successfully managed. Mean PCS and MCS quality-of-life scores decreased at 4 weeks; PCS scores then increased above pretransplant values, whereas MCS scores returned to baseline values. Estimated GFRs were similar between THINKER participants and matched recipients of HCV-negative kidneys at 6 months (median, 67.5 vs. 66.2 mL/min/1.73 m2; 95% CI for between-group difference, -4.2 to 7.5 mL/min/1.73 m2) and 12 months (median, 72.8 vs. 67.2 mL/min/1.73 m2; CI for between-group difference, -7.2 to 9.8 mL/min/1.73 m2).Limitation: Small trial.Conclusion: Twenty HCV-negative recipients of HCV-infected kidneys experienced HCV cure, good quality of life, and excellent renal function. Kidneys from HCV-infected donors may be a valuable transplant resource.Primary Funding Source: Merck. [ABSTRACT FROM AUTHOR] |
|
Copyright of Annals of Internal Medicine is the property of American College of Physicians and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
